CD177 and Alzheimer disease: Despite these challenges, biologics offer unique advantages for targeting extracellular protein aggregates, modulating cell surface receptors, and engaging immune mechanisms relevant to AD pathogenesis, suggesting continued strategic investment in BBB shuttle technologies and receptor-mediated transcytosis engineering to enable antibody-based CNS therapeutics.